

MAR 4 2004 4:34PM

AVENTIS US PAT DEPT

NO. 0047 P. 1/18

RECEIVED

CENTRAL FAX CENTER

MAR 09 2004

OFFICIAL

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:
USST98017 US PCT

Applicants:
PARKER, et al

Serial No.
09719,758

Filing Date:
January 4, 2002

Title of Invention:
MONOCLONAL ANTIBODIES DIRECTED AGAINST THE G3BP PROTEIN AND USES

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, L. R. Helms, at (571)273-0832, on
Date of Deposit March 4, 2004
Printed Name of Person Signing Certificate Jonas Pierra, Sr.

Signature

Total Number of Pages Sent: 18

Attorney: Joel B. German
Reg. No. 48,676
Group Art Unit: 1642
Examiner: L. R. Helms

TO: Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

☒ Copy of Amendment filed on December 16, 2003

☐ Fee Transmittal

☒ Copy of Statement In Support of Biological Deposit filed on December 16, 2003

☐ Petition under 37 CFR _____

☒ Copy of Statement in Support of Filing and Submission of Sequence Listing filed on December 16, 2003

☒ Other Return Postcard stamped received by the USPTO

☒ Copy of Sequence Listing filed on December 16, 2003

☒ Other Response to Examiner's Request

☐ Maintenance Fee Transmittal

Receipt Confirmed:

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com

NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

PAGE 19/36 * RCVD AT 3/4/2004 4:29:39 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/25 * DNS:2730862 * CSID:908 231 2626 * DURATION (mm-ss):07:46

03/24/2004 LBANKS 00000001 181982 09719758

01 F001P00

000.00 DA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKER, et al.

Examiner: L. R. Helms

Art Unit: 1642

Application No.: 09/719,758

Filed: January 4, 2002

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to Examiner L. R. Helms at
571-273-0862, Alexandria, VA 22313, on

March 4, 2003

Date of Transmission

Jonas Pierre
Signature

RESPONSE TO EXAMINER'S REQUEST

Mail Stop PCT
Attn: Examiner L. R. Helms
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Dear Examiner Helms,

Per your request, enclosed with this letter you will find documents the Applicants filed with their
response of December 16, 2003 to the Office Action dated July 17, 2003.

1. Amendment
2. Statement in Support of Biological Deposit
3. Statement in Support of Filing and Submission of Sequence Listing
4. Sequence Listing

Also enclosed is a copy of the return postcard stamped received by the USPTO on December 18,
2003 confirming the above documents were timely filed.

Respectfully submitted,


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. USST98017 US PCT